Company profile: Albumedix
1.1 - Company Overview
Company description
- Provider of albumin-based drug-enhancing technologies for superior biopharmaceuticals. Offers recombinant human albumin (Recombumin) as excipient, ancillary, and raw material to improve stability and quality; Veltis technology for half-life extension; albumin solutions for cell and gene therapy, vaccine stabilization, and medical device coating to enhance biocompatibility and delivery.
Products and services
- Gene therapy applications: Albumin solutions support stabilization and delivery of gene vectors to target cells in gene therapy, aiding vector stability and targeted delivery, albumin-solution–based
- Recombumin: Recombinant human albumin used as an excipient, ancillary, and raw material in diverse life science products, supporting formulation stability and quality across applications, recombinant-grade
- Veltis technology: Albumin-based system that enhances the half-life of albumin and albumin-fused drugs, enabling less frequent dosing and improved patient compliance
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Albumedix
AM-Pharma
HQ: The Netherlands
Website
- Description: Provider of biopharmaceutical therapeutics focused on inflammatory and infectious diseases, developing and commercializing products based on endogenous proteins, including ilofotase alfa, a recombinant alkaline phosphatase under development to prevent cardiac surgery-associated renal damage and as enzyme replacement therapy for hypophosphatasia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AM-Pharma company profile →
Sagimet Biosciences
HQ: United States
Website
- Description: Provider of novel therapeutics targeting FASN, including Denifanstat, an oral, once-daily selective FASN inhibitor in development for MASH, acne, and certain cancers, and TVB-3567, a pipeline FASN inhibitor planned for U.S. clinical development for acne.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sagimet Biosciences company profile →
Eagle Pharmaceuticals
HQ: United States
Website
- Description: Provider of injectable pharmaceuticals for critical care and oncology, including PEMFEXY (pemetrexed) for nonsquamous NSCLC and malignant pleural mesothelioma; BARHEMSYS (amisulpride) for prevention and treatment of postoperative nausea and vomiting; BYFAVO (remimazolam) for procedural sedation; RYANODEX (dantrolene) for malignant hyperthermia; BELRAPZO and BENDEKA (bendamustine) for CLL and indolent B-cell NHL.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eagle Pharmaceuticals company profile →
Kinarus
HQ: Switzerland
Website
- Description: Provider of biopharmaceutical therapies targeting stress-related inflammatory processes. Develops KIN001, a pamapimod/pioglitazone combination with anti-inflammatory, anti-fibrotic, and antiviral activities, in Phase 2 trials for hospitalized COVID-19 (acute and long-term), wet AMD (reducing anti-VEGF injection frequency), and IPF (reducing lung fibrosis).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kinarus company profile →
Pharmion
HQ: United States
Website
- Description: Provider of products for the treatment of hematology and oncology patients, focused on acquisition, development, and commercialization. Global biotech partnering with scientific and clinical advisors to identify and develop products for hematology and oncology markets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pharmion company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Albumedix
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Albumedix
2.2 - Growth funds investing in similar companies to Albumedix
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Albumedix
4.2 - Public trading comparable groups for Albumedix
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →